Pathology: metastatic/advanced RCC (mRCC) - 1st line (L1);
metastatic/advanced RCC (mRCC) - 1st line (L1) | ||||
CheckMate 214 (intermediate and poor risk), 2017 | CheckMate 214 (favorable risk) EXPLORATORY, 2017 | CheckMate 214 (all population), 2017 | ||
nivolumab plus ipilimumab | 3 | T1 | T1 | T1 |
sunitinib | 0 | T0 | T0 | T0 |